Cargando…

Novel forms of injectable buprenorphine and French model of opioid use disorder treatment

Detalles Bibliográficos
Autor principal:	Lapeyre-Mestre, Maryse
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521403/ https://www.ncbi.nlm.nih.gov/pubmed/33039103 http://dx.doi.org/10.1016/j.therap.2020.09.007

Ejemplares similares

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review
por: Gentile, Gaetan, et al.
Publicado: (2020)

Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database
por: Berthet, Stephanie, et al.
Publicado: (2011)

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation
por: Ling, Walter, et al.
Publicado: (2019)

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences
por: Neale, Joanne, et al.
Publicado: (2019)

Management of opioid addiction with buprenorphine: French history and current management
por: Poloméni, Pierre, et al.
Publicado: (2014)

Cannabis Use: Signal of Increasing Risk of Serious Cardiovascular Disorders
por: Jouanjus, Emilie, et al.
Publicado: (2014)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder
por: Seguí, Hemanuel Arroyo, et al.
Publicado: (2020)

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
por: Reed, Megan K, et al.
Publicado: (2022)

Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US
por: Weiner, Scott G., et al.
Publicado: (2023)

Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum]
Publicado: (2020)

Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network
por: Soeiro, Thomas, et al.
Publicado: (2021)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry
por: Palmaro, Aurore, et al.
Publicado: (2017)

Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
por: Curtiss, Frederic R.
Publicado: (2008)

Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder
por: Weintraub, Eric, et al.
Publicado: (2021)

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder
por: Laffont, Celine M., et al.
Publicado: (2022)

Personalized Care in Opioid Use Disorder maintained on Buprenorphine
por: Elarabi, H., et al.
Publicado: (2022)

Inpatient Buprenorphine Induction for Opioid Use Disorder in Pregnancy
por: Tavakoli, Amin, et al.
Publicado: (2023)

Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine
por: D'Agnone, Oscar
Publicado: (2019)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
por: Schmith, Virginia D., et al.
Publicado: (2019)

Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies
por: Lapeyre-Mestre, Maryse
Publicado: (2019)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Recovery capital among people receiving treatment for opioid use disorder with buprenorphine
por: Parlier-Ahmad, Anna Beth, et al.
Publicado: (2021)

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
por: Herring, Andrew A., et al.
Publicado: (2021)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
por: Christine, Paul J., et al.
Publicado: (2023)

Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome
por: Chavan, Niraj R., et al.
Publicado: (2017)

Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic
por: Currie, Janet M., et al.
Publicado: (2021)

Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements
por: Phillips-Jackson, Helen, et al.
Publicado: (2020)

Injection Site Reaction to Extended-Release Buprenorphine (Sublocade(®)) for Opioid Use Disorder Fourteen Days after Administration
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
por: Soyka, Michael, et al.
Publicado: (2021)

History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
por: Heidbreder, Christian, et al.
Publicado: (2023)

Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder
por: Maremmani, Icro, et al.
Publicado: (2023)

Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department
por: Martin, Alister, et al.
Publicado: (2020)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p5ufnnmf3pk4j68gnuiq5c3p1i